Pfizer/BioNTech to develop a booster dose for their COVID-19 vaccine - PMLiVE
Pfizer and its development partner BioNTech have said that they are working on a booster dose for their COVID-19 vaccine, with the aim of offering protection against new variants.
The news closely follows an announcement from Moderna, which also said that it would be testing an additional booster dose of its COVID-19 vaccine.
The aim of developing such booster doses is to determine if they could further increase the level of neutralising antibodies that fight against emerging strains.
“Every time a new variant comes up we should be able to test whether or not [our vaccine] is effective,” Pfizer chief executive officer Albert Bourla told Bloomberg.
“Once we discover something that it is not as effective, we will very, very quickly be able to produce a booster dose that will be a small variation to the current vaccine,” he added.
Read more: http://www.pmlive.com/pharma_news/pfizerbiontech_to_develop_a_booster_dose_for_their_covid-19_vaccine_1362048
The news closely follows an announcement from Moderna, which also said that it would be testing an additional booster dose of its COVID-19 vaccine.
The aim of developing such booster doses is to determine if they could further increase the level of neutralising antibodies that fight against emerging strains.
“Every time a new variant comes up we should be able to test whether or not [our vaccine] is effective,” Pfizer chief executive officer Albert Bourla told Bloomberg.
“Once we discover something that it is not as effective, we will very, very quickly be able to produce a booster dose that will be a small variation to the current vaccine,” he added.
Read more: http://www.pmlive.com/pharma_news/pfizerbiontech_to_develop_a_booster_dose_for_their_covid-19_vaccine_1362048
